06:27 , Aug 10, 2018 |  BC Week In Review  |  Company News

China Medical gains rights to Can-Fite's ADORA3 agonists

CMS Medical Venture Investment Ltd. gained rights to develop and commercialize piclidenoson (CF101) and namodenoson (CF102) in Taiwan and China, including Hong Kong and Macau, from Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-A:CANF). Can-Fite received $2...
22:12 , Jan 20, 2017 |  BC Week In Review  |  Financial News

Can-Fite completes direct public offering

Cancer and inflammatory disease company Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-M:CANF) raised $5 million through the sale of 2.5 million ADSs at $2 in a registered direct offering with institutional investors on Jan. 19. Investors...
07:00 , Jul 18, 2016 |  BC Week In Review  |  Clinical News

Piclidenoson: Phase II data

Top-line data from a double-blind, international Phase II trial in 89 patients with ocular hypertension and/or glaucoma showed that twice-daily oral CF101 missed the primary endpoint of reducing IOP from baseline to week 16 vs....
07:00 , Oct 19, 2015 |  BC Week In Review  |  Financial News

Can-Fite completes direct public offering

Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-M:CANF), Petah Tikva, Israel   Business: Cancer, Infectious, Autoimmune   Date completed: 2015-10-13   Type: Direct public offering   Raised: $4.8 million   Shares: 1.1 million   Price: $4.35  ...
07:00 , Sep 28, 2015 |  BC Week In Review  |  Financial News

Can-Fite completes direct public offering

Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-M:CANF), Petah Tikva, Israel   Business: Cancer, Infectious, Autoimmune   Date completed: 2015-09-21   Type: Direct public offering   Raised: $9 million   Shares: 2.1 million   Price: $4.35  ...
07:00 , Sep 21, 2015 |  BC Week In Review  |  Clinical News

CF102 regulatory update

FDA granted Fast Track designation to Can-Fite’s CF102 as a second-line treatment for hepatocellular carcinoma (HCC). The nucleoside adenosine A3 receptor (ADORA3) agonist is in Phase II testing to treat HCC and has Orphan Drug...
07:00 , May 11, 2015 |  BC Week In Review  |  Clinical News

IB-MECA: Additional Phase II/III data

Additional data from a double-blind, international Phase II/III trial in 326 patients with moderate to severe plaque psoriasis showed that twice-daily oral CF101 led to a 57% mean improvement in PASI score from baseline to...
07:00 , Apr 20, 2015 |  BC Week In Review  |  Company News

Can-Fite, Cipher deal

Can-Fite granted Cipher rights to commercialize Can-Fite’s CF101 in Canada to treat moderate to severe psoriasis and rheumatoid arthritis. The adenosine A3 receptor (ADORA3) agonist has completed a Phase II/III trial to treat psoriasis and...
07:00 , Apr 6, 2015 |  BC Week In Review  |  Clinical News

IB-MECA: Phase II/III data

Top-line data from a double-blind, international Phase II/III trial in 326 patients with moderate to severe plaque psoriasis showed that twice-daily oral CF101 missed the primary endpoint of improving PASI 75 response rate at week...
07:00 , Apr 6, 2015 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 4/2 cls Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-M:CANF) ROTH Capital Partners Joseph Pantginis Downgrade Neutral (from buy) -58% $2.32 Pantginis...